Vendor, Philadelphia, PA, part of Chimeron Bio Corp.
Chimeron Bio Corporation
UEI GE9QEPP5XCA3, CAGE 7KN25
1 award and $300,000 obligated between February 21, 2024 and February 12, 2025, 100% under full and open competition, against 34.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $300,000 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91024C00011Definitive Contract, February 21, 2024, Full and Open Competition After Exclusion of Sources, 34 offers | NIH NCINational Institutes of Health | Phase I Therapeutic Award: Chimeric Nanoparticle Delivery of an Sarna-Based Cancer Vaccine for Familial Adenomatous PolyposisNAICS 541715, PSC AN12 | $300,000 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 3 across 1 awards